Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

LARGE Antikörper (AA 35-142) (PE)

Der Maus Monoklonal Anti-LARGE-Antikörper wurde für FACS validiert. Er ist geeignet, LARGE in Proben von Human zu detektieren.
Produktnummer ABIN5541531

Kurzübersicht für LARGE Antikörper (AA 35-142) (PE) (ABIN5541531)

Target

Alle LARGE Antikörper anzeigen
LARGE (Like-Glycosyltransferase (LARGE))

Reaktivität

  • 10
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
Human

Wirt

  • 7
  • 2
  • 1
Maus

Klonalität

  • 9
  • 1
Monoklonal

Konjugat

  • 10
Dieser LARGE Antikörper ist konjugiert mit PE

Applikation

  • 9
  • 3
  • 3
  • 2
  • 2
  • 1
Flow Cytometry (FACS)

Klon

LARGE-02
  • Bindungsspezifität

    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 35-142

    Spezifität

    Thisa ntibody recognizes human LARGE1, a glycosyltransferase localizing mainly to the Golgi apparatus. Crossreactivity with LARGE2 was not determined.

    Immunogen

    Recombinant fragment of human LARGE1 (amino acids 35-142)

    Isotyp

    IgG2b
  • Applikationshinweise

    Flow cytometry.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C

    Informationen zur Lagerung

    Store the antibody at 2-8°C. DO NOT FREEZE! This product is photosensitive and should be protected from light. Shelf life: one year from despatch.

    Haltbarkeit

    12 months
  • Target

    LARGE (Like-Glycosyltransferase (LARGE))

    Andere Bezeichnung

    large

    Hintergrund

    LARGE1 serves as a glycosyltransferase which participates in glycosylation of the muscle membrane protein alpha-dystroglycan. Mutations of LARGE1 lead to hypoglycosylation of alpha-dystroglycan and cause congenital muscular dystrophy (MDC1D) associated with severe mental retardation. Altered alpha-dystroglycan glycosylation may also play a role in cancer, as hypoglycosylation of the protein and loss of laminin binding have been demonstrated in invasive carcinoma cells.

    UniProt

    O95461
Sie sind hier:
Chat with us!